

Masataka Tsuge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1240756/publications.pdf>

Version: 2024-02-01

188
papers

4,883
citations

87843

38
h-index

138417

58
g-index

194
all docs

194
docs citations

194
times ranked

6306
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. <i>Journal of Infectious Diseases</i> , 2023, 227, 686-695.	1.9	1
2	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	1.4	5
3	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0263844.	1.1	5
4	The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. <i>PLoS Pathogens</i> , 2022, 18, e1009983.	2.1	5
5	Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients. <i>Journal of Infection</i> , 2022, 84, 391-399.	1.7	3
6	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	1.0	1
7	A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 283-287.	0.4	14
8	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	1.4	5
9	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
10	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	0.9	5
11	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
12	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.3	2
13	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.0	0
14	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	3.5	23
15	Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. <i>Journal of Virology</i> , 2021, 95, e0049220.	1.5	14
16	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	1.0	0
17	Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1304-1311.	1.0	2
18	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.3	1
20	MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter. <i>Journal of Virology</i> , 2021, 95, e0076721.	1.5	11
21	The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. <i>Liver International</i> , 2021, 41, 2836-2848.	1.9	4
22	Are Humanized Mouse Models Useful for Basic Research of Hepatocarcinogenesis through Chronic Hepatitis B Virus Infection?. <i>Viruses</i> , 2021, 13, 1920.	1.5	1
23	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20
24	Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1268-1275.	1.1	8
25	Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.4	3
26	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	2.3	16
27	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. <i>Journal of Medical Virology</i> , 2020, 92, 210-218.	2.5	5
28	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	1.4	10
29	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.3	3
30	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	4.2	27
31	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
32	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	1.8	15
33	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	0.8	8
34	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 977-989.	2.3	8
35	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. <i>Hepatology Research</i> , 2020, 50, 1222-1233.	1.8	13
36	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration. <i>Journal of Infectious Diseases</i> , 2020, 222, 1165-1169.	1.9	10
38	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Gastroenterology</i> , 2020, 55, 1162-1170.	2.3	9
39	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	1.8	0
40	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	1.4	11
41	Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1. <i>Journal of Infectious Diseases</i> , 2020, 222, 2061-2070.	1.9	10
42	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	1.3	37
43	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
44	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.4	3
45	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
46	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
47	<i>In vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	5
48	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	1.6	13
49	Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2019, 19, 169.	0.8	14
50	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.4	6
51	Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP. <i>Scientific Reports</i> , 2019, 9, 8462.	1.6	18
52	Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. <i>Viruses</i> , 2019, 11, 263.	1.5	1
53	Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	2.0	43
54	Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2019, 54, 650-659.	2.3	6

#	ARTICLE	IF	CITATIONS
55	The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. <i>Journal of Medical Virology</i> , 2019, 91, 650-658.	2.5	26
56	Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. <i>Journal of Gastroenterology</i> , 2019, 54, 291-296.	2.3	39
57	Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. <i>Journal of General Virology</i> , 2019, 100, 1123-1131.	1.3	6
58	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
59	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28
60	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
61	Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology</i> , 2018, 53, 107-118.	2.3	17
62	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, 51-58.	1.8	110
63	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , 2018, 53, 247-257.	2.3	15
64	Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 193-204.	1.8	16
65	Involvement of <i>Porphyromonas gingivalis</i> in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 269-280.	2.3	73
66	Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. <i>Hepatology Research</i> , 2018, 48, 264-274.	1.8	3
67	Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. <i>Journal of Gastroenterology</i> , 2018, 53, 548-556.	2.3	9
68	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.2	4
69	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. <i>Virology</i> , 2018, 525, 48-61.	1.1	20
70	Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study. <i>Antiviral Therapy</i> , 2018, 23, 639-646.	0.6	9
71	Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 152-157.	1.0	15
72	<sc>CTL</sc>-associated and <sc>NK</sc> cell-associated immune responses induce different <sc>HBV DNA</sc> reduction patterns in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1555-1564.	1.0	6

#	ARTICLE	IF	CITATIONS
73	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1834-1840.	2.5	12
74	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. <i>PLoS ONE</i> , 2018, 13, e0195028.	1.1	21
75	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13
76	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. <i>BMC Cancer</i> , 2018, 18, 633.	1.1	17
77	Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. <i>Journal of General Virology</i> , 2018, 99, 1058-1065.	1.3	7
78	The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2017, 52, 113-122.	2.3	10
79	<i>IFNL4</i> polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, E5-E13.	1.8	4
80	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 179-184.	0.4	2
81	Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Oncology</i> , 2017, 92, 335-346.	0.9	11
82	<i>Wisteria floribunda</i> agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. <i>Journal of Gastroenterology</i> , 2017, 52, 1252-1257.	2.3	27
83	Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 383-387.	0.4	12
84	Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
85	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2017, 23, 239-248.	0.6	8
86	Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
87	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2017, 89, 1963-1972.	2.5	11
88	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 746-753.	2.3	19
89	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 645-650.	1.4	11
90	The risk of transient postprandial oxypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 253-262.	2.3	4

#	ARTICLE	IF	CITATIONS
91	Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. <i>Hepatology Research</i> , 2017, 47, 767-772.	1.8	15
92	The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. <i>Journal of Gastroenterology</i> , 2017, 52, 366-375.	2.3	12
93	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. <i>Journal of Medical Virology</i> , 2017, 89, 665-671.	2.5	9
94	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511.	2.3	16
95	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. <i>PLoS ONE</i> , 2017, 12, e0182710.	1.1	44
96	Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. <i>Journal of General Virology</i> , 2017, 98, 1040-1047.	1.3	17
97	Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus. <i>PLoS ONE</i> , 2017, 12, e0172412.	1.1	16
98	Combination Therapies with Daclatasvir and Asunaprevir on NS3-D168 Mutated HCV in Human Hepatocyte Chimeric Mice. <i>Antiviral Therapy</i> , 2016, 21, 307-315.	0.6	10
99	Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 524-530.	0.5	38
100	Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. <i>Hepatology Research</i> , 2016, 46, 707-712.	1.8	11
101	Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 758-764.	1.8	60
102	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2016, 46, E146-53.	1.8	19
103	Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. <i>Hepatology Research</i> , 2016, 46, 944-948.	1.8	21
104	Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing. <i>Journal of Infectious Diseases</i> , 2016, 214, 1687-1694.	1.9	11
105	Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, 1256-1263.	1.8	7
106	Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1009-1015.	1.4	52
107	Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. <i>Journal of Gastroenterology</i> , 2016, 51, 1073-1080.	2.3	21
108	Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice. <i>Virus Research</i> , 2016, 213, 62-68.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
110	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	0.6	61
111	Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. <i>Journal of Medical Virology</i> , 2015, 87, 1913-1920.	2.5	73
112	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , 2015, 45, 1047-1054.	1.8	16
113	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	1.8	42
114	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 619-627.	1.4	20
115	Factors associated with the effect of interferon sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2015, 45, 1195-1202.	1.8	22
116	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , 2015, 84, 1540-1545.	1.2	16
117	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. <i>Journal of Hepatology</i> , 2015, 63, 554-563.	1.8	29
118	Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 726-732.	1.4	18
119	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , 2015, 25, 3272-3281.	2.3	19
120	Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice. <i>Journal of Virology</i> , 2015, 89, 10087-10096.	1.5	23
121	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 516-534.	2.3	67
122	Differences in serum microRNA profiles in hepatitis B and C virus infection. <i>Journal of Infection</i> , 2015, 70, 273-287.	1.7	52
123	Role of conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	1.8	40
124	Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. <i>Hepatology Research</i> , 2014, 44, 1259-1264.	1.8	9
125	Noninvasive assessment of liver steatosis in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2014, 44, E420-7.	1.8	21
126	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. <i>Hepatology Research</i> , 2014, 44, E447-54.	1.8	13

#	ARTICLE	IF	CITATIONS
127	Ultra-deep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2105-2112.	1.4	16
128	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1548-1556.	2.3	21
129	Serum interleukin-6 associated with hepatocellular carcinoma risk: A nested case-control study. <i>International Journal of Cancer</i> , 2014, 134, 154-163.	2.3	82
130	Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1035-1042.	1.4	19
131	Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, 280-287.	1.8	17
132	Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. <i>Hepatology Research</i> , 2014, 44, 740-749.	1.8	29
133	Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2013, 48, 1188-1204.	2.3	70
134	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. <i>Journal of Gastroenterology</i> , 2013, 48, 847-855.	2.3	19
135	Availability of monitoring serum HBV DNA plus RNA during nucleotide analogue therapy. <i>Journal of Gastroenterology</i> , 2013, 48, 779-780.	2.3	5
136	A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. <i>Biochemical and Biophysical Research Communications</i> , 2013, 441, 230-235.	1.0	80
137	Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. <i>Hepatology Research</i> , 2013, 43, 1182-1189.	1.8	55
138	A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing. <i>American Journal of Gastroenterology</i> , 2013, 108, 1464-1472.	0.2	16
139	Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2013, 85, 789-798.	2.5	66
140	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. <i>Gut</i> , 2013, 62, 1055-1061.	6.1	26
141	HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e84226.	1.1	35
142	Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report. <i>Intervirology</i> , 2012, 55, 122-126.	1.2	2
143	Identification of novel hepatitis C virus deletion mutants in chronic hepatitis C patients. <i>Antiviral Therapy</i> , 2012, 17, 1551-1561.	0.6	1
144	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1467-1472.	1.4	12

#	ARTICLE	IF	CITATIONS
145	IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2012, 47, 834-844.	2.3	19
146	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. <i>Hepatology</i> , 2012, 56, 555-566.	3.6	43
147	Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 204-209.	0.4	0
148	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2012, 42, 139-149.	1.8	57
149	Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle. <i>PLoS ONE</i> , 2012, 7, e47490.	1.1	51
150	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. <i>Journal of Hepatology</i> , 2011, 54, 408-414.	1.8	72
151	Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. <i>Journal of Hepatology</i> , 2011, 54, 872-878.	1.8	45
152	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. <i>Journal of Hepatology</i> , 2011, 54, 1094-1101.	1.8	84
153	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. <i>Journal of Hepatology</i> , 2011, 55, 11-18.	1.8	9
154	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon sensitivity determining region. <i>Hepatology Research</i> , 2011, 41, 1126-1131.	1.8	2
155	Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse. <i>PLoS ONE</i> , 2011, 6, e23856.	1.1	16
156	Animal model for study of human hepatitis viruses. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 13-18.	1.4	45
157	Prediction of response to peginterferon-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. <i>Journal of Medical Virology</i> , 2011, 83, 981-988.	2.5	10
158	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peginterferon plus ribavirin therapy. <i>Journal of Medical Virology</i> , 2011, 83, 1048-1057.	2.5	45
159	Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. <i>Journal of Medical Virology</i> , 2011, 83, 1597-1607.	2.5	28
160	Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1237-1245.	3.6	30
161	Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. <i>Hepatology</i> , 2011, 54, 764-771.	3.6	31
162	Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. <i>Hepatology</i> , 2011, 54, 781-788.	3.6	70

#	ARTICLE	IF	CITATIONS
163	Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice. <i>Journal of Infectious Diseases</i> , 2011, 204, 224-228.	1.9	23
164	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	0.6	42
165	Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2010, 15, 1087-1097.	0.6	12
166	Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. <i>Journal of General Virology</i> , 2010, 91, 1668-1677.	1.3	31
167	Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3205-3211.	1.4	4
168	HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. <i>Journal of General Virology</i> , 2010, 91, 1854-1864.	1.3	90
169	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. <i>Journal of Hepatology</i> , 2010, 53, 439-443.	1.8	128
170	G to A hypermutation of TT virus. <i>Virus Research</i> , 2010, 149, 211-216.	1.1	32
171	Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1488-1496.	0.6	11
172	G to A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection. <i>Journal of Infectious Diseases</i> , 2009, 199, 1599-1607.	1.9	21
173	Ecabet sodium induces neuronal nitric oxide synthase-derived nitric oxide synthesis and gastric adaptive relaxation in the human stomach. <i>Journal of Gastroenterology</i> , 2009, 44, 1118-1124.	2.3	10
174	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. <i>Journal of Hepatology</i> , 2009, 51, 1046-1054.	1.8	30
175	A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C. <i>Gastroenterology</i> , 2009, 136, 1796-1805.e6.	0.6	42
176	The first Japanese case of COACH syndrome. <i>Hepatology Research</i> , 2009, 39, 318-323.	1.8	2
177	Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. <i>Hepatology Research</i> , 2009, 39, 1159-1168.	1.8	26
178	A case of fulminant hepatic failure caused by hepatitis E virus. <i>Clinical Journal of Gastroenterology</i> , 2008, 1, 69-74.	0.4	1
179	Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. <i>Journal of General Virology</i> , 2008, 89, 2108-2113.	1.3	34
180	Dual effect of APOBEC3G on Hepatitis B virus. <i>Journal of General Virology</i> , 2007, 88, 432-440.	1.3	65

#	ARTICLE	IF	CITATIONS
181	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. <i>FEBS Letters</i> , 2007, 581, 1983-1987.	1.3	52
182	Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. <i>Hepatology</i> , 2007, 45, 1179-1186.	3.6	57
183	Successful treatment of an entecavir-resistant hepatitis B virus variant. <i>Journal of Medical Virology</i> , 2007, 79, 1811-1817.	2.5	35
184	Enhanced SMYD3 expression is essential for the growth of breast cancer cells. <i>Cancer Science</i> , 2006, 97, 113-118.	1.7	246
185	Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3867-3874.	1.4	63
186	A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. <i>Nature Genetics</i> , 2005, 37, 1104-1107.	9.4	112
187	G to A hypermutation of hepatitis B virus. <i>Hepatology</i> , 2005, 41, 626-633.	3.6	136
188	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. <i>Hepatology</i> , 2005, 42, 1046-1054.	3.6	138